Challenges and opportunities in adapting clinical trial design for immunotherapies

Lillian L. Siu, S. Percy Ivy, Erica L. Dixon, Amy E. Gravell, Steven A. Reeves, Gary L. Rosner

Research output: Contribution to journalArticlepeer-review

Abstract

Immunotherapy adds an exciting new dimension to the treatment of cancer, joining other approaches as a key pillar in the oncotherapeutics armamentarium. Immuno-oncology agents harbor unique mechanisms of antitumor activity by leveraging the host immune system, which may result in response patterns, resistance kinetics, and toxicity profiles that differ from other systemic therapies. These features have led to many discussions on ways to optimally integrate immunotherapy into cancer clinical trials. This overview provides an introduction to the four CCR Focus articles that ensue, with special thoughts paid to clinical trial endpoints, biomarker development and validation, combination strategies, and limitations that arise with increasing use of these agents. In addition, this overview examines design concepts that may be applied to invigorate clinical trials and to maximize their impact in the immuno-oncology era.

Original languageEnglish (US)
Pages (from-to)4950-4958
Number of pages9
JournalClinical Cancer Research
Volume23
Issue number17
DOIs
StatePublished - Sep 1 2017

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Challenges and opportunities in adapting clinical trial design for immunotherapies'. Together they form a unique fingerprint.

Cite this